Results 1 to 10 of about 5,423,376 (380)

Type 2 Diabetes in Youth [PDF]

Global Pediatric Health, 2020
The incidence of type 2 diabetes in children and adolescents in the United States rose at an annual rate of 4.8% between 2002-2003 and 2014-2015. Type 2 diabetes progresses more aggressively to complications than type 1 diabetes.
Goutham Rao MD, Elizabeth T. Jensen PhD
doaj   +4 more sources

Tirzepatide for type 2 diabetes

Drugs in Context, 2023
One in ten adults worldwide is living with diabetes, with 95% having type 2 diabetes (T2D). Sustained glycaemic control in people with T2D is difficult to achieve despite recent advances in T2D management with the advent of glucagon-like peptide 1 ...
Sarah L Anderson, Joel C Marrs
doaj   +3 more sources

Saxagliptin for type 2 diabetes

Diabetes, Metabolic Syndrome and Obesity, 2010
Antonio R Chacra, MDDiabetes Center, Federal University of São Paulo, BrazilAbstract: Saxagliptin (Onglyza™) is a potent, selective, once-daily dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for improving glycemic control in ...
Antonio R Chacra, MD
doaj   +7 more sources

Pharmacogenetics in type 2 diabetes

Clinical Management Issues, 2012
n ...
Antonio Brunetti
doaj   +5 more sources

Biomarkers for type 2 diabetes

Molecular Metabolism, 2019
Background: The prevalence and incidence of type 2 diabetes (T2D), representing >90% of all cases of diabetes, are increasing rapidly worldwide.
Markku Laakso
doaj   +3 more sources

Type 2 diabetes in practice

International Journal of Integrated Care, 2002
Ronald P. Stolk
doaj   +7 more sources

Precision prevention in type 2 diabetes [PDF]

BMJ Open Diabetes Research & Care
Magdalena Sevilla-Gonzalez
doaj   +2 more sources

Real-time continuous glucose monitoring versus self-monitoring of blood glucose in adults with insulin-treated type 2 diabetes: a protocol for a randomised controlled single-centre trial

BMJ Open, 2021
Introduction Medical treatment options for type 2 diabetes (T2D) have increased over the last decade and enhance the possibility of individualised treatment strategies where insulin is still one of them. In spite of the advancements in treatment options,
Kirsten Nørgaard, Nanna Lind, Dorte Lindqvist Hansen, Signe Sætre Rasmussen   +3 more
doaj   +1 more source

Differences in lipid and blood pressure measurements between individuals with type 1 diabetes and the general population: a cross-sectional study

BMJ Open, 2023
Objectives Cardiovascular disease (CVD) is a precarious complication of type 1 diabetes (T1D). Alongside glycaemic control, lipid and blood pressure (BP) management are essential for the prevention of CVD.
Bruce H R Wolffenbuttel, Melanie M van der Klauw, Henk-Jan Aanstoot, Rita Delphine Maiko Varkevisser, Dick Mul   +4 more
doaj   +1 more source

Residual C-peptide secretion and hypoglycemia awareness in people with type 1 diabetes

BMJ Open Diabetes Research & Care, 2021
Introduction This study aimed to assess the association between fasting serum C-peptide levels and the presence of impaired awareness of hypoglycemia (IAH) in people with type 1 diabetes.Research design and methods We performed a cross-sectional study ...
Giesje Nefs, Bruce H R Wolffenbuttel, Peter R van Dijk, Petronella H Geelhoed-Duijvestijn, Henk-Jan Aanstoot, Martine J Wellens, Charlotte E Vollenbrock, Pim Dekker, Lianne S M Boesten, Martine M C de Vries-Velraeds   +9 more
doaj   +1 more source